Multicenter, single-masked, 2×3-month study comparing Ganfort and Duotrav in reducing intraocular pressure in patients with Pseudoexfoliative Glaucoma or Primary Open-Angle Glaucoma treated with Xalacom.

Diagnostic accuracy of the Heidelberg Retinal Tomograph 3.

Multicenter study on age-related corneal biomechanical changes.

The UK Glaucoma Treatment Study.

Therapeutic equivalence study of latanoprost pk and Xalatan. Randomized, double-masked clinical trial in patients with glaucoma or ocular hypertension.

Reproducibility and accuracy of Cirrus-OCT.

Comparison between the Moorfields Multi Location Motion Displacement Test (MDT) and conventional perimetry in healthy and glaucomatous eyes.

Epidemiological study of glaucoma disease in the urban population of Rome.

European retrospective study on the rate of progression of open-angle glaucoma.

Multicenter, single-masked, 3-month pilot study to evaluate efficacy and safety of fixed combination bimatoprost/timolol vs latanoprost in treatment-naïve patients with high-risk progressive open-angle glaucoma.

Learning effect of SITA-SWAP perimetry in ocular hypertensive patients.

Change in morphological and functional patterns of the ocular surface in patients treated with latanoprost after TSP 0.5% preservative-free eyedrops. Randomized, prospective, single-masked, multicenter study.

Reproducibility and accuracy of RTVue OCT.

SITA-SWAP perimetry in glaucoma patients: evaluation of RNFL alterations compared with SITA Standard.

Comparison of incidence and severity of conjunctival hyperemia with topical bimatoprost 0.01% vs latanoprost 0.005% in glaucomatous or ocular hypertensive patients.

Comparison between the effects of Bimatoprost 0.01% and Timolol 0.5% on circadian intraocular pressure.

Genetic characteristics of pigment dispersion syndrome, pigmentary glaucoma, and other forms of glaucoma.

Phase III, randomized, double-masked, 6-month study comparing preservative-free fixed-dose tafluprost 0.0015%/timolol 0.5% versus monotherapies in open-angle glaucoma or ocular hypertension.

A 2-year, multicenter, double-masked, randomized, parallel study of the safety of LUMIGAN® 0.1 mg/mL compared with LUMIGAN® 0.3 mg/mL in glaucoma or ocular hypertension.

Multicenter study comparing efficacy and tolerability of TRAVATAN® solution without BAK (Polyquad preservative) in patients previously treated with latanoprost 0.005% or bimatoprost 0.01%.

Therapeutic equivalence of Travoprost Pr and Travatan®. Randomized, double-masked trial in glaucoma or ocular hypertension.

Prospective longitudinal study for the evaluation of ocular surface disease in treatment-naïve ocular hypertensive/glaucoma patients compared with controls (SAHARA).

Influence of pupillary dilation on RNFL, ONH and GCC thickness measurements with Spectral-Domain OCT (RTVue-100).

Learning effect of Heidelberg Edge Perimetry (HEP) in ocular hypertensive patients.

Lumigan 0.1® in routine outpatient practice: retrospective study.

Efficacy of Miotrab administered three times daily in reducing intraocular pressure.

Efficacy of an ophthalmic solution containing cyanocobalamin, taurine, and hyaluronic acid in patients treated with hypotensive drugs.

Retrospective comparison of fixed combination bimatoprost/timolol vs CAI/timolol combinations in uncontrolled glaucoma or ocular hypertension.

Preservative-free Bimatoprost 0.03% (BUDPF) vs preservative-free Latanoprost 0.005% (LUDPF, Monoprost®): randomized, single-masked, 3-month, European multicenter crossover trial (SPORT).

Side effects of preservatives: clinical, cytological and instrumental assessment of ocular surface.

Evaluation of BDNF and NGF levels in plasma and tears of glaucoma patients (NTs and Glaucoma).

Proteomic study of scleral-trabecular meshwork in glaucoma.

Phase IV study on signs and symptoms in patients switched from Ganfort® to Taptiqom®.

Clinical performance of Compass perimeter in glaucoma diagnosis: comparison with HFA (CMP_002).

SPORT II: multicenter, randomized, single-masked European crossover trial comparing Bimatoprost 0.01% (BIMMD) vs Tafluprost UD 15 µg/ml (TUDPF).

Safety and efficacy of twice daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA) as adjunctive therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV).

XEN Glaucoma Treatment Register (XEN-GTR): Italian multicenter observational registry.

Efficacy of taurine and hyaluronic acid ophthalmic solution in glaucomatous or ocular hypertensive patients on chronic hypotensive therapy (OFTAL PLUS).

LOYADA: Preservative-free fixed-dose tafluprost 0.0015%/timolol 0.5% in open-angle glaucoma or ocular hypertension—real-world multicenter study.

MERCURY 3: prospective, double-masked, randomized, multicenter, active-controlled study comparing PG324 ophthalmic solution vs Ganfort®.

Pharmacokinetics of topical Citicoline: vitreous concentration in patients undergoing glaucoma or cataract surgery (OMK12017).

Ocular dominance study in glaucoma patients.

Evaluation of the effect of liposomal Citicoline solution as add-on therapy in glaucomatous patients (OMK1_LF).

CMP-003: Test-retest variability in glaucoma patients using Compass fundus perimeter.

Safety and efficacy of T4032 (bimatoprost 0.1% preservative-free) vs Lumigan 0.01% in ocular hypertension or glaucoma (LT4032-301).

CSGS: Crowd-sourced glaucoma definition for clinical research.

Phase III, multinational, randomized, investigator-masked, active-controlled study comparing DE-130A vs Xalatan® over 3 months, with 12-month open-label follow-up (CATIOPROST – 0130A01SA).

HERO: 24-hour efficacy and tolerability of preservative-free tafluprost/timolol fixed combination in patients previously treated with latanoprost preserved with BAK.

Evaluation of spatial summation within 10° of visual field: neural model for structure–function analysis.

CBASICHR0031: Basic human research study of novel glaucoma endpoints and identification of optimal populations for neuroprotection trials.

TRITON 1698-301-007: Phase 3b study evaluating duration of effect of Bimatoprost SR in open-angle glaucoma or ocular hypertension.